IP Verse

Binding Molecules Specific For Cd73 And Uses Thereof - EP3218406

The patent EP3218406 was granted to Medimmune on Oct 2, 2024. The application was originally filed on Nov 9, 2015 under application number EP15791298A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3218406

MEDIMMUNE
Application Number
EP15791298A
Filing Date
Nov 9, 2015
Status
Patent Maintained As Amended
Aug 30, 2024
Grant Date
Oct 2, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ROTHDec 23, 2021KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORFADMISSIBLE
KONIG SZYNKA TILMANN VON RENESSENov 12, 2021KONIG SZYNKA TILMANN VON RENESSE DUSSELDORFINADMISSIBLE
KONIG SZYNKA TILMANN VON RENESSENov 12, 2021KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORFINADMISSIBLE

Patent Citations (85) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2006194290
DESCRIPTIONUS2006194291
DESCRIPTIONUS2008274105
DESCRIPTIONUS2008274506
DESCRIPTIONUS2011212087
DESCRIPTIONUS2013034559
DESCRIPTIONUS2013071390
DESCRIPTIONUS2013089541
DESCRIPTIONUS2013108623
DESCRIPTIONUS2014356353
DESCRIPTIONUS2014378663
DESCRIPTIONUS2015098955
DESCRIPTIONUS2015118227
DESCRIPTIONUS4676980
DESCRIPTIONUS4683195
DESCRIPTIONUS4816567
DESCRIPTIONUS4946778
DESCRIPTIONUS5225539
DESCRIPTIONUS5530101
DESCRIPTIONUS5545806
DESCRIPTIONUS5545807
DESCRIPTIONUS5569825
DESCRIPTIONUS5585089
DESCRIPTIONUS5624821
DESCRIPTIONUS5625126
DESCRIPTIONUS5633425
DESCRIPTIONUS5639641
DESCRIPTIONUS5641870
DESCRIPTIONUS5648260
DESCRIPTIONUS5661016
DESCRIPTIONUS5693761
DESCRIPTIONUS5693762
DESCRIPTIONUS5714352
DESCRIPTIONUS5723323
DESCRIPTIONUS5750373
DESCRIPTIONUS5763192
DESCRIPTIONUS5766886
DESCRIPTIONUS5814476
DESCRIPTIONUS5817483
DESCRIPTIONUS5824514
DESCRIPTIONUS5885793
DESCRIPTIONUS5955358
DESCRIPTIONUS5969108
DESCRIPTIONUS5976862
DESCRIPTIONUS6172197
DESCRIPTIONUS6180370
DESCRIPTIONUS6204023
DESCRIPTIONUS6300064
DESCRIPTIONUS6331431
DESCRIPTIONUS6521404
DESCRIPTIONUS6544731
DESCRIPTIONUS6555313
DESCRIPTIONUS6582915
DESCRIPTIONUS6593081
DESCRIPTIONUS6653068
DESCRIPTIONUS6682736
DESCRIPTIONUS6706484
DESCRIPTIONUS6737056
DESCRIPTIONUS7083784
DESCRIPTIONUS7109003
DESCRIPTIONUS7123281
DESCRIPTIONUS7264963
DESCRIPTIONUS7332581
DESCRIPTIONUS7342110
DESCRIPTIONUS7371826
DESCRIPTIONUS7411057
DESCRIPTIONUS7538195
DESCRIPTIONUS7557189
DESCRIPTIONUS7597889
DESCRIPTIONUS7635666
DESCRIPTIONUS7658921
DESCRIPTIONUS7723270
DESCRIPTIONUS7785791
DESCRIPTIONUS7790858
DESCRIPTIONUS7807797
DESCRIPTIONUS7824679
DESCRIPTIONUS8143379
DESCRIPTIONUS8491895
DESCRIPTIONUS8779108
DESCRIPTIONUS8961967
OPPOSITIONUS2009203538
OPPOSITIONWO2014153424
OPPOSITIONWO2016055609
OPPOSITIONWO2016075099
OPPOSITIONWO2016081748

Non-Patent Literature (NPL) Citations (43) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Anonymous, "Anti-CD73 Antibody (2B6): sc-130006", Santa Cruz Biotechnology, (20160101), pages 1 - 1, Santa Cruz Biotechnology, URL: https://datasheets.scbt.com/sc-130006.pdf, (20220117), XP055879895
OPPOSITION- Anonymous, "CD73 Monoclonal Antibody (AD2), APC, eBioscienceâ„¢", Invitrogen, (20170101), pages 1 - 2, Invitrogen, URL: https://www.thermofisher.com/order/genome-database/dataSheetPdf?producttype=antibody&productsubtype=antibody_primary&productId=17-0739-42&version=202, (20220117), XP055879871
OPPOSITION- Anonymous, "NT5E/CD73 (D7F9A) Rabbit mAb #13160", Cell Signaling, (20150101), pages 1 - 2, XP055879926
OPPOSITION- Anonymous, "Product Datasheet 5'-Nucleotidase/CD73 Antibody (4G4) NBP1-60135-0.05mg Earn rewards for product reviews and publications", Noviusbio, (20200506), pages 1 - 3, Noviusbio, URL: https://www.novusbio.com/PDFs/NBP1-60135-0.05mg.pdf, (20220117), XP055879883
OPPOSITION- Anonymous, "Product Datasheet 5'-Nucleotidase/CD73 Antibody (AD2) NBP2-48480 Earn rewards for product reviews and publications", Novusbio, (20120101), pages 1 - 5, Novusbio, URL: https://www.novusbio.com/PDFs3/NBP2-48480.pdf, (20220117), XP055879876
OPPOSITION- Anonymous, "Product datasheet Anti-CD73 antibody [7G2] ab54217 ", ABCAM, (20090101), pages 1 - 3, ABCAM, (20220117), XP055879813
OPPOSITION- Cytiva, "Outstanding sensitivity for confident SPR interaction analysis", (20220101), pages 1 - 8, XP093104401
OPPOSITION- HÄUSLER et al., "Anti- CD 39 and anti- CD 73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion", Am J Transl Res, (20140000), vol. 6, no. 2, pages 129 - 139, XP055240896
OPPOSITION- Ntokou Aglaia, Et Al, "CALL FOR PAPERS Bioengineering the Lung Characterization of the platelet-derived growth factor receptor-alpha-positive cell lineage during murine late lung development", J Physiol Lung Cell Mol Physiol, (20150828), pages 942 - 958, J Physiol Lung Cell Mol Physiol, URL: https://journals.physiology.org/doi/pdf/10.1152/ajplung.00272.2014, (20220117), XP055879917
OPPOSITION- Sachsenmeier Kris F, Et Al, "Development of a Novel Ectonucleotidase Assay Suitable for High-Throughput Screening", Journal of Biomolecular Screening, (20120101), pages 993 - 998, Journal of Biomolecular Screening, URL: https://journals.sagepub.com/doi/pdf/10.1177/1087057112443987, (20220117), XP055879969
OPPOSITION- Sult Erin, "Checkpoint inhibitor combinations with MEDI9447 in a human mixed leukocyte reaction", AACR 106th Annual Meeting, (20150409), pages 1 - 1, XP055879961
OPPOSITION- Supernat Anna, Et Al, "CD73 expression as a potential marker of good prognosis in breast carcinoma", Appl Immunohistochem Mol Morphol, (20120101), vol. 20, pages 103 - 107, XP055879938
OPPOSITION- Thompson Lf, Et Al, "Antibodies to 5'-nucleotidase (CD73), a glycosyl-phosphatidylinositol- anchored protein, cause human peripheral blood T cells to proliferate", The Journal of immunology (1950), Am Assoc Immnol, United States, United States, (19890915), pages 1815 - 1821, The Journal of immunology (1950), URL: https://www.jimmunol.org/content/jimmunol/143/6/1815.full.pdf, (20220117), XP055879929
OPPOSITION- Heuts Dominic P. H. M., Et Al, "Crystal Structure of a Soluble Form of Human CD73 with Ecto-5′-Nucleotidase Activity", CHEMBIOCHEM, (20121105), vol. 13, no. 16, doi:10.1002/cbic.201200426, ISSN 1439-4227, pages 2384 - 2391, XP055879943
OPPOSITION- M H Van Regenmortel, "What is a B-cell epitope?", M H Van Regenmortel, Mike Schutkowski, Ulrich Reineke (eds.), Epitope Mapping Protocols : Second Edition; IN: Methods in Molecular Biology; ISSN 1064-3745; Vol. 524, US , Humana Press , (20090101), vol. 524, pages 3 - 20, doi:10.1007/978-1-59745-450-6_1, ISBN 978-1-59745-450-6, XP055642505
OPPOSITION- C OLGAN et al., "Physiological roles for ecto-5'-nucleotidase CD 73", Purinergic Signalling, (20060000), vol. 2, no. 2, doi:10.1007/s11302-005-5302-5, pages 351 - 360, XP019410884
OPPOSITION- Loisel, S. Ohresser, M. Pallardy, M. Dayde, D. Berthou, C. Cartron, G. Watier, H., "Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment", Critical Reviews in Oncology/Hematology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20070307), vol. 62, no. 1, doi:10.1016/j.critrevonc.2006.11.010, ISSN 1040-8428, pages 34 - 42, XP005912444
OPPOSITION- Knapp Karen, Et Al, "Crystal Structure of the Human Ecto-5′-Nucleotidase (CD73): Insights into the Regulation of Purinergic Signaling", Structure, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20121201), vol. 20, no. 12, doi:10.1016/j.str.2012.10.001, ISSN 0969-2126, pages 2161 - 2173, XP055879947
OPPOSITION- ANTONIOLI et al., "Anti - CD 73 in cancer immunotherapy: awakening new opportunities", Trends Cancer, (20160000), doi:10.1016/j.trecan.2016.01.003, pages 95 - 109, XP055529454
OPPOSITION- GOUDENEGE et al., "Myoblasts derived from normal hESCs and dystrophic hiPSCs efficiently fuse with existing muscle fibers following transplantation", Mol Ther, (20120000), vol. 20, no. 11, doi:10.1038/mt.2012.188, pages 2153 - 2167, XP055457899
OPPOSITION- HOLLIGER PHILIPP; HUDSON PETER J, "ENGINEERED ANTIBODY FRAGMENTS AND THE RISE OF SINGLE DOMAINS", Nature Biotechnology, Nature Publishing Group US, New York, New York, (20050901), vol. 23, no. 9, doi:10.1038/nbt1142, ISSN 1087-0156, pages 1126 - 1136, XP008076746
OPPOSITION- Nuno Bandeira, Pham Victoria, Pevzner Pavel, Arnott David, Lill Jennie R, "Automated de novo protein sequencing of monoclonal antibodies", Nature Biotechnology, Gale Group Inc., (20081201), vol. 26, no. 12, doi:10.1038/nbt1208-1336, ISSN 10870156, pages 1336 - 1338, XP055023375
OPPOSITION- Antonioli Luca, Et Al, "Immunity, inflammation and cancer: a leading role for adenosine", Nature Reviews Cancer, Nature Pub. Group, London, London , (20131201), vol. 13, no. 12, doi:10.1038/nrc3613, ISSN 1474-175X, pages 842 - 857, XP055879955
OPPOSITION- CARTER P J, "POTENT ANTIBODY THERAPEUTICS BY DESIGN", Nature Reviews Immunology, Nature Publishing Group UK, London, London, (20060407), vol. 6, doi:10.1038/nri1837, ISSN 1474-1733, pages 343 - 357, XP007901440
OPPOSITION- STAGG et al., "Anti- CD 73 antibody therapy inhibits breast tumor growth and metastasis", PNAS, (20100000), vol. 107, no. 4, doi:10.1073/pnas.0908801107, pages 1547 - 1552, XP055245510
OPPOSITION- Grozio Alessia, Et Al, "CD73 Protein as a Source of Extracellular Precursors for Sustained NAD+ Biosynthesis in FK866-treated Tumor Cells", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20130723), vol. 288, no. 36, doi:10.1074/jbc.M113.470435, ISSN 0021-9258, pages 25938 - 25949, XP055879886
OPPOSITION- Delcourt Nicolas, Et Al, "Targeted Identification of Sialoglycoproteins in Hypoxic Endothelial Cells and Validation in Zebrafish Reveal Roles for Proteins in Angiogenesis", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20150201), vol. 290, no. 6, doi:10.1074/jbc.M114.618611, ISSN 0021-9258, pages 3405 - 3417, XP055879897
OPPOSITION- GEOGHEGAN et al., "Inhibition of CD 73 AMP hydrolysis by a therapeutic antibody with a dual, non- competitive mechanism of action", MABS, (20160000), vol. 8, no. 3, doi:10.1080/19420862.2016.1143182, pages 454 - 467, XP055533459
OPPOSITION- AIRAS et al., "Differential regulation and function of CD 73, a glycosyl-phosphatidylinositol- linked 70-kD adhesion molecule, on lymphocytes and endothelial cells", J Cell Biol, (19970000), vol. 136, no. 2, doi:10.1083/jcb.136.2.421, pages 421 - 431, XP055242069
OPPOSITION- THOMSON et al., "Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5'- nucleotidase CD 73", Tissue Antigens, (19900000), vol. 35, no. 1, doi:10.1111/j.1399-0039.1990.tb01750.x, pages 9 - 19, XP008131950
OPPOSITION- Anonymous, "NT5E monoclonal antibody (M01), clone 4C4-2B5", Abnova, doi:10.1111/nan.12221, (20150101), pages 1 - 1, Abnova, URL: https://www.abnova.com/products/products_detail.asp?catalog_id=H00004907-M01, (20220117), XP055879910
OPPOSITION- Garcia-Esparcia Paula, Et Al, "Purine metabolism gene deregulation in Parkinson's disease : Purine in PD", NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY., BLACKWELL SCIENTIFIC PUBLICATIONS, LONDON, GB, GB , (20151201), vol. 41, no. 7, doi:10.1111/nan.12221, ISSN 0305-1846, pages 926 - 940, XP055879903
OPPOSITION- ZHANG, "CD 73: a novel target for cancer immunotherapy", Cancer Res, (20100000), vol. 70, no. 16, doi:10.1158/0008-5472.CAN-10-1544, pages 6407 - 6411, XP055252656
OPPOSITION- ASCIERTO et al., "Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types", Clin Cancer Res, (20130000), doi:10.1158/1078-0432.CCR-12-2982, pages 1009 - 1020, XP055124339
OPPOSITION- ALLARD et al., "Targeting CD 73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs", Clin Cancer Res, (20130000), vol. 19, no. 20, doi:10.1158/1078-0432.CCR-13-0545, pages 5626 - 5635, XP055216360
OPPOSITION- YOUNG et al., "Taraetina cancer-derived adenosine: new therapeutic approaches", Cancer Discov, (20140000), vol. 4, no. 8, doi:10.1158/2159-8290.CD-14-0341, pages 879 - 888, XP055242089
OPPOSITION- Steven Rust et al, "Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer c", MOLECULAR CANCER, BIOMED CENTRAL, LONDON, GB, GB , (20130213), vol. 12, no. 1, doi:10.1186/1476-4598-12-11, ISSN 1476-4598, page 11, XP021139556
OPPOSITION- Fausther Michel, Et Al, "NT5E Mutations That Cause Human Disease Are Associated with Intracellular Mistrafficking of NT5E Protein", PLoS ONE, doi:10.1371/journal.pone.0098568, (20140601), pages 1 - 11, PLoS ONE, URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0098568&type=printable, (20220117), XP055879890
OPPOSITION- Cinti Alessandro, Et Al, "Simultaneous Overexpression of Functional Human HO-1, E5NT and ENTPD1 Protects Murine Fibroblasts against TNF-α-Induced Injury In Vitro", PLOS ONE, doi:10.1371/journal.pone.0141933, (20151001), pages 1 - 23, PLOS ONE, URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0141933&type=printable, (20220117), XP055879866
OPPOSITION- ALLARD et al., "Targeting CD 73 and downstream adenosine receptor signaling in triple- neaative breast cancer", Exp Opin Ther Targets, (20140000), vol. 18, no. 8, doi:10.1517/14728222.2014.915315, pages 863 - 881, XP055267045
OPPOSITION- ALLARD et al., "Targeting CD 73 and downstream adenosine receptor signaling in triple- neaative breast cancer", Exp Opin Ther Targets, (2014), vol. 18, no. 8, doi:10.1517/14728222.2014.915315, pages 863 - 881, XP055267045
OPPOSITION- Saraswathy Nachimuthu, Ponnusamy Ramalingam, "Section 14: Protein sequencing techniques", Concepts and techniques in genomics and proteomics , WOODHEAD PUBLISHING LIMITED, (20110701), pages 193 - 201, doi:10.1533/9781908818058.193, ISBN 978-1-907568-10-7, XP093127370
OPPOSITION- TERP et al., "Anti-Human CD 73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD 73 expressed on the surface of cancer cells", J Immunol, (20130000), vol. 191, doi:10.4049/jimmunol.1301274, pages 4165 - 4173, XP055245512

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents